(Q35160569)

6 August 2017

1 reference

title

Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides (English)

1 reference

6 August 2017

Arie Admon

1

1 reference

6 August 2017

Eilon Barnea

series ordinal

2

1 reference

6 August 2017

Tamar Ziv

series ordinal

3

1 reference

6 August 2017

23 June 2003

1 reference

Molecular & Cellular Proteomics

6 August 2017

1 reference

6 August 2017

2

1 reference

6 August 2017

388-398

1 reference

6 August 2017

6

1 reference

Self peptides and the peptidic self

6 August 2017

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Cut and trim: generating MHC class I peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The nature of molecular recognition by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Therapeutic vaccination for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Peptide Vaccination in Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A fresh look at tumor immunosurveillance and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Challenges in the development of effective peptide vaccines for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Clinical cancer vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Peptide-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Immunotherapy against antigenic tumors: a game with a lot of players

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Cancer: the evolved consequence of a destabilized genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Adjuvant immunotherapy for solid tumors: from promise to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A proteomic approach to the identification of lung cancer markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Identification of tumor-associated antigens using proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Serological identification of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Serological analysis of human tumor antigens: molecular definition and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Exploitation of the B cell repertoire for the identification of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Proteome analysis and its impact on the discovery of serological tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Reading within the lines: naturally processed peptides displayed by MHC class I molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Inducing autoimmune disease to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Optimizing vaccine design for cellular processing, MHC binding and TCR recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Dendritic cell vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Neural network-based prediction of candidate T-cell epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Prediction of MHC class I binding peptides using profile motifs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Prediction of promiscuous peptides that bind HLA class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Prediction of MHC class I binding peptides, using SVMHC

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

PAProC: a prediction algorithm for proteasomal cleavages available on the WWW.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Using the World Wide Web for predicting CTL epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Prospects for immunotherapy of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Contribution of mass spectrometry to contemporary immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A post-translational modification of nuclear proteins, N(G),N(G)-dimethyl-Arg, found in a natural HLA class I peptide ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Complexity among constituents of the HLA-B*1501 peptide motif.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Genetic engineering of an H-2Dd/Q10b chimeric histocompatibility antigen: purification of soluble protein from transformant cell supernatants

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Immunochemical analysis of a recombinant, genetically engineered, secreted HLA-A2/Q10b fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Analysis of the association of peptides of optimal length to class I molecules on the surface of cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Peptide-induced conformational change of the class I heavy chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

CDR3 loop flexibility contributes to the degeneracy of TCR recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Dynamics of protein turnover, a missing dimension in proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Quantitating protein synthesis, degradation, and endogenous antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

To DRiP or not to DRiP: generating peptide ligands for MHC class I molecules from biosynthesized proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Protein degradation and the generation of MHC class I-presented peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A comparison of selected mRNA and protein abundances in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Protease degradomics: a new challenge for proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Antigen processing by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The nature of the MHC class I peptide loading complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

ER aminopeptidases generate a unique pool of peptides for MHC class I molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Proteolysis and class I major histocompatibility complex antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Functional regulation of immunoproteasomes and transporter associated with antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Error-tolerant identification of peptides in sequence databases by peptide sequence tags

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A statistical basis for testing the significance of mass spectrometric protein identification results

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Biomedical informatics for proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Molecular immunology databases and data repositories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Population of the HLA ligand database

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Matching peptide mass spectra to EST and genomic DNA databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Harnessing the cellular immune system to the gene-prediction cart

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Description and prediction of peptide-MHC binding: the 'human MHC project'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Generating MHC class I ligands from viral gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Towards patient-specific tumor antigen selection for vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Cancer immunoprevention: tracking down persistent tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Genetic engineering of T cell specificity for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Loss of HLA class-I alleles, heavy chains and β2-microglobulin in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Excess β2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The major substrates for TAP in vivo are derived from newly synthesized proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

The thymus and negative selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

MHC-binding peptides as immunotherapeutics for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

MAGE-B5, MAGE-B6, MAGE-C2, andMAGE-C3: four new members of theMAGE family with tumor-specific expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Peptide motif of the class I molecule HLA-B*1503

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: estimation of the affinity of a T cell receptor for MHC

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

Tumor-specific T-bodies: towards clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R300004-MCP200

10.1074/MCP.R300004-MCP200

21 January 2018

Identifiers

DOI

0 references

1 reference